MonzrMAl MalkiMD

Hematology • Duarte, CA

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

Associate Professor, Hematology and Hematopoietic Cell Transplantation

Join to view full profile

Dr. Al Malki is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Al Malki's full profile

Already have an account?

Office
1500 E Duarte Rd
Department of Hematology HCT
Duarte, CA 91010
Phone+1 626-256-4673

Fax+1 626-218-5310

Summary

Dr. Monzr Al Malki is a hematologist in Duarte, CA and is affiliated with City of Hope's Helford Clinical Research Hospital. He received his medical degree from Damascus University Faculty of Medicine and has been in practice 14 years. He also speaks multiple languages, including Arabic and Spanish. He specializes in hematologic oncology and myeloproliferative disorder hematology-oncology and is experienced in aplastic anemia, hematopoietic stem cell transplantation, acute myeloid leukemia, hodgkin's lymphoma, and multiple myeloma.

Education & Training

Roger Williams Medical CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
Damascus University Faculty of MedicineClass of 2003
Cleveland Clinic FoundationResidency, Internal Medicine

Certifications & Licensure

CA State Medical License 2014 - 2025
MA State Medical License 2008 - 2016
RI State Medical License 2008 - 2016
OH State Medical License 2005 - 2008

Clinical Trials

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease Start of enrollment: 2016 Aug 01
Completed
Phase 2
Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma Start of enrollment: 2015 Jan 20
Active, not recruiting
Phase 2
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy
No longer available
BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma Start of enrollment: 2016 Dec 02
Terminated
Phase 2
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis Start of enrollment: 2017 May 24
Recruiting
Phase 1
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Start of enrollment: 2017 May 30
Completed
Phase 2
Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome Start of enrollment: 2018 Jul 06
Recruiting
Phase 1
Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) Start of enrollment: 2019 Jun 14
Active, not recruiting
Not Applicable
TAC/MTX vs. TAC/MMF/PTCY for Prevention of Graft-versus-Host Disease and Microbiome and Immune Reconstitution Study (BMT CTN 1703/1801) Start of enrollment: 2019 Jun 25
Completed
Phase 3
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia Start of enrollment: 2020 Feb 07
Recruiting
Phase 2
Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Start of enrollment: 2020 Feb 20
Active, not recruiting
Phase 1, Phase 2
SARS-CoV-2 Donor-Recipient Immunity Transfer Start of enrollment: 2020 Sep 23
Completed
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Start of enrollment: 2021 Sep 30
Recruiting
Phase 2
Study of GDX012 in Patients With MRD Positive AML Start of enrollment: 2021 Aug 13
Terminated
Phase 1
MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies Start of enrollment: 2021 Jun 16
Terminated
Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia Start of enrollment: 2014 Feb 10
Active, not recruiting
Phase 2
Magrolimab in Combination With Azacitidine After Allogeneic HCTin Treating Patients With High-Risk AML or MDS Start of enrollment: 2024 Jun 09
Suspended
Phase 1
Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies Start of enrollment: 2023 Jun 16
Recruiting
Phase 1
Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants Start of enrollment: 2022 Nov 23
Recruiting
Phase 2
A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor Transplantation Start of enrollment: 2022 Nov 01
Recruiting
Phase 1
A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2023 Jul 11
Recruiting
Phase 1, Phase 2
Passive Music Intervention for the Reduction of Anxiety in Patients Undergoing Bone Marrow Aspiration and/or Biopsy Start of enrollment: 2024 Apr 22
Recruiting
Phase 3
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Start of enrollment: 2023 Dec 08
Recruiting
Phase 2
Multi-antigen Specific CD8+ T Cells with Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients with Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation from a Matched Donor
Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis Start of enrollment: 2022 Mar 30
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

11 citations
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Re...
Naval G Daver, Paresh Vyas, Suman Kambhampati, Monzr M Al Malki, Richard A Larson
Journal of Clinical Oncology. 2023-11-01
44 citations
Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
David A Sallman, Monzr M Al Malki, Adam S Asch, Eunice S Wang, Joseph G Jurcic
Journal of Clinical Oncology. 2023-05-20
53 citations
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
Ibrahim Aldoss, Sanjeet Dadwal, Jianying Zhang, Bernard Tegtmeier, Matthew Mei
Blood Advances. 2019-12-10

Abstracts/Posters

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
Monzr M. Al Malki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Updated Analysis: Novel Machine-Learning-Based Sepsis Prediction Model for Patients Undergoing Hematopoietic Stem Cell Transplantation (Early Sepsis Prediction/Identif...
Monzr M. Al Malki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Optimization of Tacrolimus Serum Levels When Combined with Post-Transplant Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis after Hematopoietic Cell Transplan...
Monzr M. Al Malki, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
MIPSS70+ V2.0 and Revised Cytogenetics Changes Predict Outcomes of Allogeneic Transplantation with Fludarabine and Melphalan Conditioning in Patients with Myelofibrosis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Clinical Outcomes of MDS Patients Who Were Allogeneic Hematopoietic Stem Cell Transplant Candidates but Did Not Proceed with Transplantation
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

NMDP and CIBMTR to Present New, Promising Stem Cell Transplantation Trial Data Using Mismatched, Unrelated Donors at 2024 ASCO Annual MeetingMay 23rd, 2024
Half-Matches Open Door to Bone Marrow Transplant for More PatientsMay 6th, 2019